ライフサイエンスコーパス: PCV

1 PCV administered 6 months after PPV stimulated modest in

2 PCV coverage was assessed from the Australian Childhood

3 PCV failure is rare and, compared to PCV7 serotypes, the

4 PCV patients had large, vascularized, peaked PEDs associ

5 PCV patients on pro re nata (PRN) anti-vascular endothel

6 PCV reduced pneumococcal colonization rate, density, and

7 PCV-7 vaccination lowered the density of VT and of NVT p

8 Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none fo

9 Use of a 2+1 PCV schedule with booster at age 9 months in a resource-

10 13 of 14 non-PCV lesions but misidentified 1 PCV lesion (false positive).

11 Out of 7 PCV eyes, focal choroidal vascular dilation was noted in

12 ith 3 main underlying etiologies: AMD (76%), PCV (9%), and CSC (3%).

13 reports from high-income countries giving a PCV booster dose.

14 te how spatial epidemiological analysis of a PCV trial can assist in developing vaccination strategie

15 ars were age-appropriately vaccinated with a PCV.

16 th a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in

17 ted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors.

18 mors assigned to IGS-9 benefit from adjuvant PCV.

19 e same RT followed by six cycles of adjuvant PCV.

20 In contrast, PPV administered 6 months after PCV caused dramatic increases in the levels of IgG and O

21 ine serotypes among children and women after PCV introduction.

22 seen on indocyanine green angiography in all PCV eyes.

23 eumonia group than in the PPV (P = .000) and PCV (P = .029) groups, L-selectin was expressed more fre

24 l AMD (213.7 mum to 190.3 mum, P < .001) and PCV (240.8 mum to 213.4 mum, P < .01) eyes, but no signi

25 study included patients with typical AMD and PCV who received anti-VEGF therapy over a 12-month perio

26 d after anti-VEGF therapy in typical AMD and PCV.

27 The etiology and pathogenesis of CNV and PCV are not well understood.

28 ed rates of IPD by sex, race, age group, and PCV era were calculated.

29 PPV and PCV stimulated similar IgG levels and OPK at 4-8 weeks a

30 et of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, al

31 ness was not significantly different between PCV and typical AMD eyes, and was thicker in the study e

32 detection of PCV and differentiation between PCV and occult CNV in this selected clinic population.

33 llow ophthalmologists to distinguish between PCV and occult CNV, decreasing the need for ICGA and the

34 munized adults with schedules combining both PCV and 23vP and investigated B-cell responses to establ

35 Both PCVs are immunogenic and induce measurable IgG, PC, and

36 ups and persisted after introduction of both PCVs.

37 o impute the indirect protection afforded by PCV in unvaccinated age groups, including those in high-

38 nce interval [CI], .50-.57), but differed by PCV era.

39 Subjects received PPV followed by PCV 6 months later, or vice versa.

40 djusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P = .01).

41 e speculated that reduction of complex OM by PCVs would be associated with reduction of non-pneumococ

42 oversion (ECV), pharmacologic cardioversion (PCV), or AF ablation and subsequent outcomes in patients

43 that increased HTRA1 is sufficient to cause PCV and is a significant risk factor for CNV.

44 To characterize PCV effect on adult serotype patterns, we reviewed the l

45 Childhood PCV programs have provided considerable benefit, with su

46 D incidence prior to and following childhood PCV immunization in South Africa.

47 INTERPRETATION: Population childhood PCV programmes will lead, on average, to substantial pro

48 opies of double-stranded porcine circovirus (PCV) DNA in tandem (0.8 copy of PCV type 1 [PCV1], 0.95

49 f new vaccines on pneumococcal colonization; PCV provides a gold standard against which to test these

50 was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1

51 ring development of the posterior crossvein (PCV) in the pupal wing.

52 More data from countries with differing PCV schedules and from the PCV13 era are needed to infor

53 After 9 years of timely 3-dose PCV coverage of >92%, all-age IPD in Australia almost ha

54 The overall incidence of ECV, PCV, or AF ablation was 1.45 per 100 patient-years (n =

55 al detachments (PEDs) attributable to either PCV or occult CNV were retrospectively reviewed by a gra

56 , results from studies suggest that existing PCVs can prevent early episodes of disease associated wi

57 ive study of Asian patients with extrafoveal PCV, confirmed on indocyanine green angiography and trea

58 visual outcome in most eyes with extrafoveal PCV, including eyes with fluid or blood affecting the fo

59 lance of colonization prior to and following PCV use can be used to impute the indirect protection af

60 The use of PPV as a booster following PCV causes early increases in antibody levels, but the l

61 asive pneumococcal disease changes following PCV introduction in unvaccinated populations, updating t

62 iated with PCV7 serotypes declined following PCV implementation, with a proportionally greater declin

63 A total of 4154 reports of events following PCV were submitted to VAERS, for a rate of 13.2 reports

64 , the PCV-encoded Rep' protein essential for PCV DNA replication in mammalian cells was not required

65 (CNV) subtype, the genetic risk factors for PCV are relatively unknown.

66 e alternative to the traditional process for PCV development.

67 median survival by treatment (4.6 years for PCV plus RT v 4.7 years for RT; hazard ratio [HR] = 0.79

68 H1 mutations), that especially benefits from PCV chemotherapy.

69 The Gambian PCV programme reduced the incidence of invasive pneumoco

70 67Ytk but showed enhanced activity with (3)H-PCV in vitro and with (18)F-FHBG in vivo.

71 (TK) assay using 8-(3)H-penciclovir (8-(3)H-PCV) as substrate.

72 yluracil ((3)H-FEAU), (3)H-pencyclovir ((3)H-PCV), and (3)H-GCV and by drug sensitivity assays.

73 163 patients, 77 had typical AMD and 86 had PCV.

74 e during the preceding period of heptavalent PCV (PCV7) use, overall and by serotype category.

75 for the above SD OCT features in identifying PCV lesions.

76 e pneumococcal disease (IPD) to determine if PCV-associated indirect protection was relatively reduce

77 In PCV on PRN anti-VEGF therapy, increases in PED area and

78 IPD cases in PCV-eligible children aged <5 years (born since 4 Septem

79 ates were similar to the observed changes in PCV-unvaccinated children and adults, but not among chil

80 g, 15A and 35B) not currently represented in PCV formulations increased modestly.

81 onia was unique yet it was closer to that in PCV recipients than in PPV recipients.

82 Local variations in PCV uptake (and receipt of the booster dose) might influ

83 the targeted serotypes, local variations in PCV uptake among children could influence disease patter

84 ic features and the choroidal vasculature in PCV.

85 Reductions in VTs and changes in VATs in PCV communities did not show evidence of variation by ST

86 s, including low-income countries, introduce PCVs and as higher valency PCVs are used.

87 The odds of pre-PCV7 VT IPD, PCV schedule, PCV coverage and whether a catch up campai

88 Licensed PCVs currently cover only 13 of the over 90 serotypes of

89 pneumonia, the effect of PPV is short-lived; PCV stimulates a more prolonged response.

90 a 1 + 1 schedule in countries with a mature PCV programme and established herd immunity is likely to

91 assuming that VT are eliminated in a mature PCV programme, that full serotype replacement occurs in

92 e reported impact on childhood IPD of mature PCV programmes; the ratio of predicted and observed inci

93 L has enabled the licensing of effective new PCVs, serotype-specific correlates of protection vary wi

94 Non-PCV serotypes causing the highest QALY loss were 22F and

95 SD OCT correctly excluded 13 of 14 non-PCV lesions but misidentified 1 PCV lesion (false positi

96 The addition of PCV (procarbazine, lomustine, and vincristine) chemother

97 The addition of PCV chemotherapy to RT improves PFS without excessive CF

98 lysis, for 2-year survivors, the addition of PCV to RT conferred a survival advantage, suggesting a d

99 However, the addition of PCV to RT did not result in significantly higher rates o

100 e survival was observed with the addition of PCV, but at the cost of increased toxicity.

101 er than 2 years coincided with the advent of PCV-13.

102 se results demonstrate a 3-D architecture of PCV that may be helpful for a better understanding of th

103 The choice of PCV schedule will require a balance between the need for

104 circovirus (PCV) DNA in tandem (0.8 copy of PCV type 1 [PCV1], 0.95 copy of PCV2) with two origins o

105 The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in ana

106 to RT alone or RT followed by six cycles of PCV.

107 ion of LGO/LGOA received up to six cycles of PCV.

108 features above allowed for good detection of PCV and differentiation between PCV and occult CNV in th

109 ients, 37 had an ICGA-confirmed diagnosis of PCV and 14 had occult CNV.

110 pneumococcal vaccination received 1 dose of PCV.

111 ict the direct and indirect effectiveness of PCV by analyzing serotype-specific colonization prevalen

112 improve understanding of the epidemiology of PCV and potentially inform the development of new and mo

113 A total of 163 episodes of PCV failure were confirmed in 161 children over 8 years

114 e cause for optimism that rapid evolution of PCV escape strains with drug resistance or high virulenc

115 increased HTRA1 induced cardinal features of PCV, including branching networks of choroidal vessels,

116 En face SS OCT imaging of PCV eyes demonstrated the relationship between larger pi

117 The impact of PCV on nasopharyngeal (NP) colonization is essential to

118 dividuals in which to estimate the impact of PCV on transmission.

119 INTERPRETATION: The introduction of PCV in The Gambia was associated with a moderate impact

120 AERS in the first 2 years after licensure of PCV described generally minor adverse events previously

121 MLST in Utah children after the licensure of PCV-7.

122 t in the United States prior to licensure of PCV-7.

123 During follow-up, there was no occurrence of PCV.

124 hing vascular networks (BVNs), and origin of PCV using optical coherence tomography angiography (OCTA

125 natomy, pathophysiology, and pathogenesis of PCV.

126 remained modestly elevated after receipt of PCV.

127 determine the response rate and toxicity of PCV administered before radiation therapy in patients wi

128 8 years of PCV use in England and Wales has reduced the overall inc

129 r dose) might influence the effectiveness of PCVs in preventing pneumococcal disease in adults.

130 magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease.

131 rsimonious model that predicts the impact of PCVs from the odds of vaccine serotype (VT) among carrie

132 A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income pop

133 occal OM incidence after the introduction of PCVs.

134 ollected before and after the routine use of PCVs (1998-2012).

135 s after PCV7 introduction, supporting use of PCVs.

136 of age or older in the era of routine use of PCVs.

137 months compared with a three-dose prime-only PCV schedule provided non-inferior immunogenicity in ear

138 efractive error, diagnosis of typical AMD or PCV, number or type of anti-VEGF injections, PDT therapy

139 s provide reassurance that, similar to PCV7, PCVs with additional serotypes can also prevent transmis

140 ggests a limited effect of current pediatric PCVs against IPD in the elderly.

141 e randomly assigned to RT (54 Gy) or RT plus PCV.

142 atures above detected 35 of 37 true-positive PCV lesions but missed 2 ICGA-confirmed lesions (false n

143 differed between the pre-PCV period and post-PCV era.

144 e used in this simple model to estimate post-PCV changes in IPD incidence.

145 udies can be used to accurately monitor post-PCV changes in the incidence of invasive pneumococcal di

146 ed child-mother dyads from 2007 to 2009 (pre-PCV era), in 2010 (7-valent PCV era), and in 2012 (13-va

147 Three subperiods were defined: pre-PCV, PCV7, and PCV13.

148 Three sub-periods were established: pre-PCV, PCV7, and PCV13.

149 asive pneumococcal diseases (IPD) in the pre-PCV era.

150 ; 95% CI, .61-1.61) differed between the pre-PCV period and post-PCV era.

151 , 3.2-3.6) per 100 000 population in the pre-PCV period to 2.4 (95% CI, 2.2-2.7) in the PCV13 period.

152 Of all-NTHi cases in the pre-PCV period, 34% were mixed with Streptococcus pneumoniae

153 (VT) among carriers and IPD cases in the pre-PCV period, assuming that VT are eliminated in a mature

154 Compared with the pre-PCV period, OM caused by PCV7 plus serotype 6A and the 5

155 (95% confidence interval) comparing the pre-PCV to the PCV13 period were 0.02 (0.01-0.04), 0.12 (0.0

156 erotypes (P < 0.001 when compared to the pre-PCV-7 period).

157 old or born during the study period received PCV-7.

158 urves separated significantly, favoring RT + PCV.

159 d for adult patients with LGG receiving RT + PCV versus RT alone.

160 time and 5-year PFS rates for RT versus RT + PCV were 4.4 years versus not reached and 46% versus 63%

161 time and 5-year OS rates for RT versus RT + PCV were 7.5 years versus not reached and 63% versus 72%

162 for an additional 5 years was 74% with RT + PCV versus 59% with RT alone (HR, 0.52; 95% CI, 0.30 to

163 herapy (RT) alone versus 12.8 years after RT/PCV (P = .0349; hazard ratio, 2.18; 95% CI, 1.06 to 4.50

164 median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in

165 from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI

166 The odds of pre-PCV7 VT IPD, PCV schedule, PCV coverage and whether a catch up campaign was used fo

167 th significant decreases in six of the seven PCV serotypes.

168 d to describe children who died of IPD since PCV introduction in England and Wales.

169 mounted adequate responses to the other six PCV serotypes.

170 few children more than once after successive PCV doses, including allergic reactions, prolonged or ab

171 The primary outcomes were survival (PCV v TMZ) and 12-week progression-free survival (PFS; T

172 PDT combined with IVB for symptomatic PCV was temporarily superior to PDT monotherapy, and the

173 Targeted PCV vaccination of African infants in a setting with hig

174 More broadly, our findings suggest that PCV-specialized angioblasts contribute not only to the f

175 These results suggest that PCVs have an important impact on hospitalizations for al

176 The PCV group had a significantly reduced rate of 6B coloniz

177 l group was 62.4 (+/-12.1) years and for the PCV group was 68.3 (+/-5.2) years.

178 bitory and positive activities of Sog in the PCV and early embryo, respectively.

179 Serotype replacement observed in the PCV communities was due to a diverse population of STs,

180 ty vs. day) was significantly reduced in the PCV compared with control group (geometric mean, 259 vs.

181 more frequently in the PPV group than in the PCV group (P = .014); and CLA was expressed more frequen

182 Density of colonization was reduced in the PCV group compared with the control group following inoc

183 ents completing 9 months of treatment in the PCV, TMZ-5, and TMZ-21 arms were 17%, 26%, and 13%, resp

184 In the PCV-13 premarket years, there was a stable rate ratio (R

185 t also a positive effect on signaling in the PCV.

186 owever, Tld cannot substitute for Tlr in the PCV; in fact, misexpressed Tld can cause loss of the PCV

187 Interestingly, the PCV-encoded Rep' protein essential for PCV DNA replicati

188 We show that tlr mutants lack the PCV as a result of too little Bmp signaling.

189 with baseline, after the introduction of the PCV programme, the incidence of invasive pneumococcal di

190 ing levels of Sog can also cause loss of the PCV, indicating that Sog has not only an inhibitory but

191 fact, misexpressed Tld can cause loss of the PCV.

192 cterial replication machinery to support the PCV DNA replication process echoes previous suggestions

193 ible patients were randomly assigned: 148 to PCV plus RT and 143 to RT.

194 rty-seven patients were randomly assigned to PCV (224 patients) or TMZ (sub-random assignment: TMZ-5

195 They were randomly assigned to PCV (n = 49) or hepatitis A (control, n = 50) vaccinatio

196 Prior to PCV introduction, at least 53% of pneumonia cases were d

197 on, and were not associated with response to PCV (possibly because of the small sample size).

198 frequency of positive antibody responses to PCV than to PPV (57% vs 36%) (P = .004) and greater mean

199 Responses to PCV were greater in frequency and magnitude for all sero

200 ynergistically to increase susceptibility to PCV.

201 longer than those with noncodeleted tumors (PCV plus RT: 14.7 v 2.6 years, HR = 0.36, 95% CI, 0.23 t

202 DNA species, including a requirement of two PCV Oris and the virus-encoded replication initiator Rep

203 Twenty-two PCV patients (mean age 69.6 years) were included.

204 s, 143 patients underwent ECV, 142 underwent PCV, and 79 underwent catheter ablation.

205 lled fellow eyes in patients with unilateral PCV.

206 roduction of pneumococcal conjugate vaccine (PCV) are attributable to the vaccine's impact on coloniz

207 munized with pneumococcal conjugate vaccine (PCV) both before and after IPD, the proportion with IgG

208 hedules with pneumococcal conjugate vaccine (PCV) differ among countries regarding the number of dose

209 s before the pneumococcal conjugate vaccine (PCV) era.

210 ct of infant pneumococcal conjugate vaccine (PCV) immunization on pneumococcal colonization among hum

211 of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries was enhanced by indirect pro

212 e benefit of pneumococcal conjugate vaccine (PCV) in protecting against invasive pneumococcal disease

213 Pneumococcal conjugate vaccine (PCV) is now recommended for use in adults in the United

214 of 13-valent pneumococcal conjugate vaccine (PCV) on colonization.

215 Pneumococcal conjugate vaccine (PCV) was introduced into Alberta, Canada's routine child

216 the 7-valent pneumococcal conjugate vaccine (PCV) would enhance these responses.

217 nsure of the pneumococcal conjugate vaccine (PCV-7) in 2000.

218 ved 7-valent pneumococcal conjugate vaccine (PCV-7), while in another 10 villages (the control group)

219 ; n = 14) or pneumococcal conjugate vaccine (PCV; n = 11).

220 PPV, protein-conjugate pneumococcal vaccine (PCV), and immunologic "priming" with PCV followed by "bo

221 ed with the advent of the 13-valent vaccine (PCV-13) in 2010.

222 could evade pneumococcal conjugate vaccines (PCV) by modifying, mutating, or deleting vaccine-serotyp

223 h childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated popul

224 polysaccharide-protein conjugated vaccines (PCV), although highly effective in infants, offer any im

225 tric use of pneumococcal conjugate vaccines (PCVs) affect rates of adult serotype-specific invasive p

226 Pneumococcal conjugate vaccines (PCVs) are being used worldwide.

227 Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invasive pneumo

228 Pneumococcal conjugate vaccines (PCVs) are used in many low-income countries but their im

229 y effective pneumococcal conjugate vaccines (PCVs) are used in national immunization programs in many

230 Pneumococcal conjugate vaccines (PCVs) have been introduced worldwide.

231 Pneumococcal conjugate vaccines (PCVs) have demonstrated efficacy against childhood pneum

232 rollout of pneumococcal conjugate vaccines (PCVs) have exceeded predictions of vaccine impact.

233 Pneumococcal conjugate vaccines (PCVs) have substantially reduced morbidity and mortality

234 Pneumococcal conjugate vaccines (PCVs) have substantially reduced the burden of pneumococ

235 The use of pneumococcal conjugate vaccines (PCVs) in children has a strong indirect effect on diseas

236 oduction of pneumococcal conjugate vaccines (PCVs) in five countries in the Americas.

237 e effect of pneumococcal conjugate vaccines (PCVs) in low-income countries.

238 Use of pneumococcal conjugate vaccines (PCVs) in resource-poor countries has focused on early in

239 Pneumococcal conjugate vaccines (PCVs) prevent vaccine serotype (VT) invasive disease; no

240 Pneumococcal conjugate vaccines (PCVs) target only a few serotypes that cause otitis medi

241 oduction of pneumococcal conjugate vaccines (PCVs).

242 Pneumococcal conjugated vaccines (PCVs) impact on complex otitis media (OM; including recu

243 extensive pediatric uptake of higher-valence PCVs.

244 ured the effects of introducing high-valency PCVs on the incidence of invasive pneumococcal disease i

245 ntries, introduce PCVs and as higher valency PCVs are used.

246 effects after introduction of higher valency PCVs.

247 e potential indirect protection of 10-valent PCV (PCV10) in a developing country setting is unknown.

248 l that examined the efficacy of an 11-valent PCV among children less than 2 y of age in Bohol, Philip

249 itional serotypes contained in the 13-valent PCV (PCV13) but not in PCV7.

250 cine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countrie

251 and was gradually replaced by the 13-valent PCV (PCV13) starting in November 2010.

252 uctions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with declines in IPD rates i

253 and May 2012-April 2013 (period 2; 13-valent PCV era).

254 0 (7-valent PCV era), and in 2012 (13-valent PCV era).

255 with a further reduction following 13-valent PCV introduction from April 2010 to 0.39/100000 in 2013-

256 2009 and gradually replaced by the 13-valent PCV starting in November 2010.

257 olysaccharide vaccine (PPSV23) and 13-valent PCV within specified geographic and time conditions.

258 Although the introductions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated wit

259 h at least 3 or at least 4 doses of 7-valent PCV (PCV7) from the state immunization registry.

260 The 7-valent PCV (PCV7) was introduced to the Israeli National Immuni

261 before and after administration of 7-valent PCV (PCV7) were available from England and Wales, the Ne

262 2 years investigating the effect of 7-valent PCV (PnCRM7) on NP colonization among American Indian in

263 n May 2010-February 2011 (period 1; 7-valent PCV era) and May 2012-April 2013 (period 2; 13-valent PC

264 007 to 2009 (pre-PCV era), in 2010 (7-valent PCV era), and in 2012 (13-valent PCV era).

265 lated mortality rate declined after 7-valent PCV introduction from 1.25/100000 children in 2006-2007

266 The impact of the 7-valent PCV on all-serotype invasive pneumococcal disease (IPD)

267 The 7-valent PCV was introduced to Israel's national immunization pro

268 ponses to establish whether PCV7 (a 7-valent PCV) induced T-dependent responses in adults, to assess

269 uped serotypes contained in the seven-valent PCV (PCV7), and 9.5 years (6.1-16.6) for the grouped six

270 ne (PCV13) alone and four use the ten-valent PCV (PCV10) and PCV13.

271 ue and UK prescribed concentration or value (PCV) for arsenic of 10 mug/L in 5% of properties surveye

272 including polypoidal choroidal vasculopathy (PCV) and macular fibrosis or atrophy.

273 ents with polypoidal choroidal vasculopathy (PCV) had a worse final outcome.

274 Polypoidal choroidal vasculopathy (PCV), a subtype of 'wet' age-related macular degeneratio

275 (CNV) and polypoidal choroidal vasculopathy (PCV).

276 atment in polypoidal choroidal vasculopathy (PCV).

277 enesis of polypoidal choroidal vasculopathy (PCV).

278 in the floor of the posterior cardinal vein (PCV).

279 or procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT),

280 nt procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglial tumors.

281 of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).

282 arbazine, lomustine (CCNU), and vincristine (PCV) is active in patients with recurrent LGO/LGOA, we h

283 to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone.

284 of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recu

285 nt procarbazine, lomustine, and vincristine (PCV; respectively) to radiotherapy did not produce super

286 Patients in whom PCV was identified on OCTA were examined to define chara

287 e FGD6 gene as significantly associated with PCV (P = 2.19 x 10(-16), odds ratio (OR) = 2.12) but not

288 ) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that t

289 Of the 93 eyes with PCV at baseline, 33 eyes (35.5%) in 31 patients had extr

290 scular abnormalities in 7 out of 7 eyes with PCV, and in 2 out of 3 enrolled fellow eyes in patients

291 study included 10 eyes from 6 patients with PCV and 10 eyes from 5 age-matched normal subjects.

292 Patients with PCV were younger (67.6 vs 72.5 years, P < .01) and recei

293 accine (PCV), and immunologic "priming" with PCV followed by "boosting" with PPV in adults who had re

294 red the immunogenicity of revaccination with PCV ( n = 131) or PPV (n = 73) among HIV-infected adults

295 rsons with HIV infection, revaccination with PCV was only transiently more immunogenic than PPV, and

296 of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.

297 en younger than 18 years and vaccinated with PCV.

298 Vaccination with PCV before and/or after IPD was associated with lower Ig

299 Because vaccination of children with PCVs protects adults from the targeted serotypes, local

300 When children are vaccinated with PCVs, other serotypes that are not targeted by the vacci